Clinical Trials Directory

ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia

The purpose of this study is to understand physician treatment decisions in selecting specific second line treatments in pediatric ITP and to determine the effectiveness of different second line ITP treatments. Eligible patients are those ages 1-18 years who are starting on a new second line treatment for ITP, defined as any treatment other than IVIG, steroids, anti-D globulin, or aminocaproic acid. Enrolled patients remain on the study for approximately one year.

Stanford is now accepting new patients for this trial. Please contact Michael Jeng at for more information.



  • drug : Second Line ITP agents

Phase: N/A


Ages Eligible For Study:

1 Year - 18 Years

Inclusion Criteria

- Immune Thrombocytopenia or Evans Syndrome - Ages > 12 months to <18 years - Starting a new second line therapy as defined as any therapy except IVIG, steroids, anti-D globulin, or aminocaproic acid - Starting a single agent/monotherapy

External Links

Explore related trials

Contact information

Primary Contact:

Michael Jeng

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: